Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

498 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tuberculosis in the United States: Medical Consultation Services Provided by 5 Tuberculosis Regional Training and Medical Consultation Centers, 2013-2017.
Goswami ND, Mase S, Griffith D, Bhavaraju R, Lardizabal A, Lauzardo M, Chen L, Wilson J, Chappelle C, Haley CA. Goswami ND, et al. Among authors: haley ca. Open Forum Infect Dis. 2019 Apr 4;6(6):ofz167. doi: 10.1093/ofid/ofz167. eCollection 2019 Jun. Open Forum Infect Dis. 2019. PMID: 31205971 Free PMC article.
Multidrug-resistant tuberculosis care in the United States.
Gobaud AN, Haley CA, Wilson JW, Bhavaraju R, Lardizabal A, Seaworth BJ, Goswami ND. Gobaud AN, et al. Among authors: haley ca. Int J Tuberc Lung Dis. 2020 Apr 1;24(4):409-413. doi: 10.5588/ijtld.19.0515. Int J Tuberc Lung Dis. 2020. PMID: 32317065 Free PMC article.
Novel 6-Month Treatment for Drug-Resistant Tuberculosis, United States.
Haley CA, Macias P, Jasuja S, Jones BA, Rowlinson MC, Jaimon R, Onderko P, Darnall E, Gomez ME, Peloquin C, Ashkin D, Goswami ND. Haley CA, et al. Emerg Infect Dis. 2021 Jan;27(1):332-4. doi: 10.3201/eid2701.203766. Epub 2020 Nov 23. Emerg Infect Dis. 2021. PMID: 33227229 Free PMC article.
Implementation of Bedaquiline, Pretomanid, and Linezolid in the United States: Experience Using a Novel All-Oral Treatment Regimen for Treatment of Rifampin-Resistant or Rifampin-Intolerant Tuberculosis Disease.
Haley CA, Schechter MC, Ashkin D, Peloquin CA, Peter Cegielski J, Andrino BB, Burgos M, Caloia LA, Chen L, Colon-Semidey A, DeSilva MB, Dhanireddy S, Dorman SE, Dworkin FF, Hammond-Epstein H, Easton AV, Gaensbauer JT, Ghassemieh B, Gomez ME, Horne D, Jasuja S, Jones BA, Kaplan LJ, Khan AE, Kracen E, Labuda S, Landers KM, Lardizabal AA, Lasley MT, Letzer DM, Lopes VK, Lubelchek RJ, Patricia Macias C, Mihalyov A, Misch EA, Murray JA, Narita M, Nilsen DM, Ninneman MJ, Ogawa L, Oladele A, Overman M, Ray SM, Ritger KA, Rowlinson MC, Sabuwala N, Schiller TM, Schwartz LE, Spitters C, Thomson DB, Tresgallo RR, Valois P, Goswami ND; BPaL Implementation Group. Haley CA, et al. Clin Infect Dis. 2023 Oct 5;77(7):1053-1062. doi: 10.1093/cid/ciad312. Clin Infect Dis. 2023. PMID: 37249079 Free PMC article.
Treatment of Latent Tuberculosis Infection.
Haley CA. Haley CA. Microbiol Spectr. 2017 Apr;5(2). doi: 10.1128/microbiolspec.TNMI7-0039-2016. Microbiol Spectr. 2017. PMID: 28409555 Free article. Review.
498 results